

# Contrast Induced Nephropathy - Pipeline Review, H1 2020

<https://marketpublishers.com/r/CCE3737BE97EN.html>

Date: February 2020

Pages: 45

Price: US\$ 2,000.00 (Single User License)

ID: CCE3737BE97EN

## Abstracts

Contrast Induced Nephropathy - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contrast Induced Nephropathy - Pipeline Review, H1 2020, provides an overview of the Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline landscape.

Contrast-induced nephropathy (CIN) is defined as the impairment of renal function (measured as either a 25% increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44  $\mu$ mol/L) increase in absolute SCr value after 48-72 hrs contrast administration). Symptoms include feeling more tired, poor appetite, swelling in the feet and ankles, puffiness around the eyes, or dry and itchy skin. Risk factors include age, diabetes, decreased kidney function and congestive heart failure. Treatment includes electrolyte management.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contrast Induced Nephropathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Contrast Induced Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 3 and 1 respectively.

Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Contrast Induced

Nephropathy (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Contrast Induced Nephropathy - Overview

Contrast Induced Nephropathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Contrast Induced Nephropathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Contrast Induced Nephropathy - Companies Involved in Therapeutics Development

Daiichi Sankyo Co Ltd

Pharming Group NV

Radikal Therapeutics Inc

Saghmos Therapeutics Inc

Contrast Induced Nephropathy - Drug Profiles

carperitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

conestat alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-911 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-62516 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Contrast Induced Nephropathy - Dormant Projects

Contrast Induced Nephropathy - Discontinued Products

Contrast Induced Nephropathy - Product Development Milestones

Featured News & Press Releases

Oct 17, 2018: Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST) in Contrast-induced Nephropathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Contrast Induced Nephropathy, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Contrast Induced Nephropathy - Pipeline by Daiichi Sankyo Co Ltd, H1 2020

Contrast Induced Nephropathy - Pipeline by Pharming Group NV, H1 2020

Contrast Induced Nephropathy - Pipeline by Radikal Therapeutics Inc, H1 2020

Contrast Induced Nephropathy - Pipeline by Saghmos Therapeutics Inc, H1 2020

Contrast Induced Nephropathy - Dormant Projects, H1 2020

Contrast Induced Nephropathy - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Contrast Induced Nephropathy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Daiichi Sankyo Co Ltd

Pharming Group NV

Radikal Therapeutics Inc

Saghmos Therapeutics Inc



## I would like to order

Product name: Contrast Induced Nephropathy - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/CCE3737BE97EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCE3737BE97EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970